Bristol-Myers Squibb Company

BMY

US1101221083

Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques. The United States account for 70.1% of net sales.

Employees

34,100

Sector

Pharmaceuticals

Calendar

08:00am - Citi Global Healthcare Conference

More about the company

Income Statement and Estimates

income-statement-evolution-chart BRISTOL-MYERS-SQUIBB-COMP

More financial data

Analysis / Opinion

Christopher Boerner, CEO of Bristol-Myers: A pipeline of 16 treatments, with a focus on neuroscience and oncology

January 09, 2024 at 01:06 pm EST

More Strategies

Ratings

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

59.94USD

Average target price

60.43USD

Spread / Average Target

+0.82%

Consensus

Profit revisions

estimates-change-chart BRISTOL-MYERS-SQUIBB-COMP

Estimate revisions

Quarterly revenue - Rate of surprise

quality-estimates-chart BRISTOL-MYERS-SQUIBB-COMP

Company calendar

Real-time Estimate Cboe BZX Other stock markets 03:48:12 2024-12-03 pm EST			5-day change	1st Jan Change
58.82 ^USD	-1.88%		-0.12%	+14.34%

02:00pm	Bristol-Myers Squibb Company Presents at Citi's 2024 Global Healthcare Conference, Dec-03-2024 08:00 AM
02:00pm	AI Proteins, Inc. Announces Research Collaboration and Option Agreement with Bristol Myers Squibb for Miniprotein-Based Therapeutics Valued Up to $400 Million	CI

Bristol-Myers Squibb Company Presents at Citi's 2024 Global Healthcare Conference, Dec-03-2024 08:00 AM	08:00am
AI Proteins, Inc. Announces Research Collaboration and Option Agreement with Bristol Myers Squibb for Miniprotein-Based Therapeutics Valued Up to $400 Million	08:00am	CI
Astrazeneca's Enhertu, Orpathys Among 91 Drugs Added to China's National Reimbursement Drug List	Nov. 29	MT
Bernstein Adjusts Price Target on Bristol-Myers Squibb to $62 From $56, Keeps Market Perform Rating	Nov. 25	MT
Wall Street warms to AI's glow	Nov. 22
Bristol Myers: presents new data to ASH	Nov. 19	CF
Bristol Myers Squibb?s Presentations at ASH 2024 Reinforce Strength of Hematology Portfolio and Scientific Advances in Differentiated Research Platforms	Nov. 19	CI
Bristol-Myers Squibb Company Presents at Jefferies London Healthcare Conference 2024, Nov-19-2024 09:30 AM	Nov. 19
Wells Fargo Adjusts Price Target on Bristol-Myers Squibb to $60 From $52, Maintains Equalweight	Nov. 18	MT
HSBC Adjusts Bristol-Myers Squibb Price Target to $58 From $50, Maintains Hold Rating	Nov. 15	MT
Bristol-Myers Says European Committee Recommends Approval of Opdivo-Yervoy Combination Therapy for Colorectal Cancer	Nov. 15	MT
Bristol Myers Squibb's Augtyro Recommended for EU Approval	Nov. 15	MT
Bristol Myers: positive opinion from CHMP for Opdivo	Nov. 15	CF
Bristol Myers Gets CHMP Backing for Augtyro Cancer Drug	Nov. 15	DJ
Bristol-Myers Says European Committee Recommends Approval of Repotrectinib	Nov. 15	MT
Bristol Myers: positive opinion for repotrectinib in U	Nov. 15	CF
Bristol-Myers Squibb Faces $6.7 Billion Lawsuit in Renewed Cancer Drug Delay Case	Nov. 15	MT
Bristol Myers Squibb Receives Positive CHMP Opinion for Repotrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer and Advanced NTRK-Positive Solid Tumors	Nov. 15	CI
JPMorgan Adjusts Price Target on Bristol-Myers Squibb to $70 From $64, Keeps Overweight Rating	Nov. 13	MT
Analyst recommendations: Spotify, Starbucks, Tesla, Block, Coinbase...	Nov. 13
Daiwa Upgrades Bristol-Myers Squibb to Outperform From Neutral, Adjusts Price Target to $65 From $50	Nov. 13	MT
UBS Raises Bristol-Myers Squibb Price Target to $60 From $54, Maintains Neutral Rating	Nov. 12	MT
With Trump, market mayhem meets Bitcoin boom	Nov. 12
Goldman Sachs Adjusts Bristol-Myers Squibb Price Target to $65 From $62, Maintains Buy Rating	Nov. 12	MT
Leerink Partners Upgrades Bristol-Myers Squibb to Outperform From Market Perform, Adjusts Price Target to $73 From $55	Nov. 12	MT

Bristol-Myers Squibb Company

Equities

BMY